Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys - PubMed (original) (raw)
Clinical Trial
Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys
William Trattler et al. Clin Ther. 2006 Nov.
Abstract
Background: Keratoconjunctivitis sicca is a common eye condition characterized by itchiness, redness, and dryness due to a lack of tear production or abnormalities in the tear film. Cyclosporine works to increase the production of natural tears, which contain nutrients and proteins not found in artificial tears.
Objective: The purpose of this report was to assess the association between self-reported compliance with topical cyclosporine 0.05% emulsion and the onset of effects of increased tear production in patients with dry eye.
Methods: Practicing physicians were asked to identify patients for whom treatment with cyclosporine was appropriate and who were willing to participate in the study. Patients who agreed to participate were given medication samples and study materials. The participants were asked to respond to automated survey questions before they used cyclosporine and 30 and 60 days after initiating cyclosporine. Participants were asked how frequently they used the medication, how rapidly their symptoms were relieved, and whether they intended to continue using cyclosporine.
Results: Of the 5367 patients initially enrolled in the study, 3145 (59%) patients completed the baseline and 60-day follow-up surveys. The mean age of the participants was 60 years; 2677 (85%) of them were women, and 468 (15%) were men. Compliance with cyclosporine therapy was reported as follows: 2477 (79%) participants said they used cyclosporine twice daily as prescribed by their physicians, 468 (15%) reported missing some doses of cyclosporine, and 189 (6%) reported missing -50% or > or = 50% of the doses. The effects of increased tear production were reported to occur significantly sooner in participants who complied with cyclosporine treatment as prescribed than in those who did not comply with treatment (P < 0.01). Among those who complied with treatment, 1822 (73%) participants reported experiencing the effects of increased tear production in < 5 weeks compared with 468 (70%) participants who did not comply with treatment. Overall, the mean rate of satisfaction with cyclosporine was 7.5 on a scale from 0 (not at all satisfied) to 10 (very satisfied). Participants who reported using cyclosporine twice daily as prescribed gave satisfaction with cyclosporine a mean rating of 7.7 compared with 7.3 given by those who missed some doses and 5.3 from those who missed approximately 50% or > or = 50% of the doses (P < 0.01). An intention to continue using cyclosporine was reported by 2611 (83%) participants.
Conclusion: The results of this study in participants using cyclosporine for dry eye in an actual-practice setting suggest an association between patient-reported compliance with medication and more rapid onset of the effects of increased tear production.
Similar articles
- The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca.
Stonecipher K, Perry HD, Gross RH, Kerney DL. Stonecipher K, et al. Curr Med Res Opin. 2005 Jul;21(7):1057-63. doi: 10.1185/030079905X50615. Curr Med Res Opin. 2005. PMID: 16004673 Clinical Trial. - Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Barber LD, et al. Ophthalmology. 2005 Oct;112(10):1790-4. doi: 10.1016/j.ophtha.2005.05.013. Ophthalmology. 2005. PMID: 16102833 Clinical Trial. - Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Pflugfelder SC, et al. Cornea. 2008 Jan;27(1):64-9. doi: 10.1097/ICO.0b013e318158f6dc. Cornea. 2008. PMID: 18245969 - Antiinflammatory therapy for dry eye.
Pflugfelder SC. Pflugfelder SC. Am J Ophthalmol. 2004 Feb;137(2):337-42. doi: 10.1016/j.ajo.2003.10.036. Am J Ophthalmol. 2004. PMID: 14962426 Review. - Topical ophthalmic cyclosporine: pharmacology and clinical uses.
Donnenfeld E, Pflugfelder SC. Donnenfeld E, et al. Surv Ophthalmol. 2009 May-Jun;54(3):321-38. doi: 10.1016/j.survophthal.2009.02.002. Surv Ophthalmol. 2009. PMID: 19422961 Review.
Cited by
- Ophthalmology Provider Ratings and Patient, Disease, and Appointment Factors.
Han MM, Hsueh J, Chen AX, Greenlee TE, Conti TF, Rose SL, Singh RP, Rachitskaya AV. Han MM, et al. J Patient Exp. 2021 Aug 9;8:23743735211033750. doi: 10.1177/23743735211033750. eCollection 2021. J Patient Exp. 2021. PMID: 34395846 Free PMC article. - Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study.
Byun YS, Rho CR, Cho K, Choi JA, Na KS, Joo CK. Byun YS, et al. Korean J Ophthalmol. 2011 Dec;25(6):369-74. doi: 10.3341/kjo.2011.25.6.369. Epub 2011 Nov 22. Korean J Ophthalmol. 2011. PMID: 22131772 Free PMC article. - Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies.
Shen Lee B, Kabat AG, Bacharach J, Karpecki P, Luchs J. Shen Lee B, et al. Clin Ophthalmol. 2020 Jan 14;14:119-126. doi: 10.2147/OPTH.S228838. eCollection 2020. Clin Ophthalmol. 2020. PMID: 32021076 Free PMC article. Review. - Impact of dry eye disease treatment on patient quality of life.
Lin CW, Lin MY, Huang JW, Wang TJ, Lin IC. Lin CW, et al. Front Med (Lausanne). 2024 Feb 28;11:1305579. doi: 10.3389/fmed.2024.1305579. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38482530 Free PMC article. Review. - Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease.
White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. White DE, et al. Clin Ophthalmol. 2020 Mar 19;14:875-883. doi: 10.2147/OPTH.S233194. eCollection 2020. Clin Ophthalmol. 2020. PMID: 32256045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources